Apogee Therapeutics announced that its half‑life extended TSLP antibody APG333 achieved positive interim Phase 1 results in healthy volunteers, demonstrating a 55‑day half‑life and sustained suppression of eosinophils and IL‑5 for six months after a single 1,000 mg dose. The drug was well tolerated, with only mild adverse events such as headache and upper respiratory tract infection and no Grade 3 or serious drug‑related events.
The extended pharmacokinetic profile supports a dosing interval of three to six months, a major advantage over current bi‑weekly biologics. The data also underpin the development of APG273, a co‑formulation of APG777 and APG333, which could offer quarterly or less frequent dosing for asthma and eosinophilic esophagitis.
The company completed a $345 million public offering, bringing its cash, cash equivalents, and marketable securities to $913 million as of September 30, 2025. Compared with the prior quarter, cash rose from $588.9 million to $913 million, and from $621.2 million at June 30, 2025, underscoring a significant liquidity boost that extends the runway into the second half of 2028.
CEO Michael Henderson emphasized that the strong Phase 1 data and the new capital position position Apogee for a “transformative 2026,” with four key clinical readouts scheduled for 2026, including APG777 in asthma and atopic dermatitis and a head‑to‑head trial of APG279 against Dupixent.
Analysts at Craig‑Hallum and other firms maintained “Buy” ratings, citing the robust pipeline and the extended dosing advantage. The announcement reinforced investor confidence in Apogee’s capital efficiency and adaptive trial designs, which aim to reduce Phase 3 failure risk.
The extended half‑life and quarterly dosing potential could improve patient adherence and reduce administration costs, positioning Apogee against competitors such as Sanofi and Regeneron. The $345 million infusion also allows the company to invest in upcoming Phase 3 studies without immediate cash burn concerns, supporting long‑term value creation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.